TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 15832145
Drug: Weekly physiotherapy
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly physiotherapy
Study: 2194788
Drug: Fenugreek seeds
Normalized name: FENUGREEK SEED
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenugreek seeds (100 g, divided into two doses during lunch and dinner)
Study: 7393831
Drug: Intravenous naloxone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous naloxone administration
Study: 29232438
Drug: Rituximab as
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab as part of salvage therapy
Study: 26384447
Drug: TDV (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDV (various dosages including increased TDV-4 and one-tenth TDV dose)
Study: 20840689
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and root planing (SRP) plus oral hygiene instruction
Study: 20840689
Drug: Oral hygiene
Normalized name: HYDROGEN PEROXIDE 2.94 mL in 2.94 mL ORAL SPRAY [OROXID Forte Oral Hygiene]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral hygiene instruction only (control)
Study: 20840689
Drug: Successful periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Successful periodontal treatment
Study: 20840689
Drug: Unsuccessful periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unsuccessful periodontal treatment
Study: 17547876
Drug: Intravaginal metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravaginal metronidazole gel
Study: 16389542
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg Delta(9)-tetrahydrocannabinol (dronabinol)
Study: 26939313
Drug: Seretide (western
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seretide (western medication)
Study: 22907998
Drug: Therapeutic hypothermia
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapeutic hypothermia (TH) with cooling gel packs to a target temperature of 33‐34°C for 72 h
Study: 21212385
Drug: 20 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 Gy of radiation therapy (TE18 trial)
Study: 21212385
Drug: Para‐aortic radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Para‐aortic radiation therapy (TE10 trial)
Study: 21212385
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (TE19 trial)
Study: 16705841
Drug: Basic treatment
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic treatment plus acu-moxibustion group (treated with oral medicine like those in the control group plus acupuncture and moxibustion)
Study: 3327022
Drug: Vincristine combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vincristine combination therapy (COP)
Study: 3327022
Drug: Vindesine combination
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vindesine combination therapy (CEP)
Study: 28730676
Drug: Intranasal glucagon
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal glucagon (ING) 1 mg
Study: 24731783
Drug: Natalizumab treatment
Normalized name: Natalizumab
DrugBank: Natalizumab (DB00108)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Natalizumab treatment after 6 months
Study: 24731783
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no natalizumab treatment)
Study: 23525453
Drug: Intrapleural bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intrapleural bevacizumab (300 mg) with cisplatin (30 mg)
Study: 23525453
Drug: Intrapleural cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrapleural cisplatin (30 mg) alone
Study: 18568412
Drug: Magnesium citrate
Normalized name: Magnesium Citrate
DrugBank: Magnesium (DB14513)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnesium citrate (610 mg orally every other day for 2 months)
Study: 18568412
Drug: Calcium acetate
Normalized name: Calcium Acetate
DrugBank: Calcium sulfate (DB15533)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium acetate therapy (control group)
Study: 12901032
Drug: Both COX‐2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both COX‐2 inhibitors
Study: 8972810
Drug: Braun Oral‐B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Braun Oral‐B Plaque Remover (Braun/Oral‐B, Kronberg, Germany)
Study: 6084675
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g 1 h pre‐operatively and every 6 h for 48 h (vein graft patients)
Study: 6084675
Drug: Cefazolin 1
Normalized name: cefazolin 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 1 g (synthetic graft patients)
Study: 6084675
Drug: Cefazolin 2
Normalized name: cefazolin 2000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 2 g (synthetic graft patients)
Study: 27687379
Drug: i-Gel (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-Gel (Group I: n = 17)
Study: 27687379
Drug: i-Gel (Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-Gel (Group I)
Study: 23424961
Drug: Fluoxetine (Flu)
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fluoxetine (Flu) 20 mg/day
Study: 18384551
Drug: Nicotine patch
Normalized name: Nicotine Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine patch (7 mg)
Study: 18384551
Drug: No patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: No patch
Study: 10674566
Drug: Intranasal budesonide
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intranasal budesonide (400 microg) once daily for 4 weeks
Study: 10674566
Drug: Aqueous spray
Normalized name: Pen-Aqueous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aqueous spray (256 microg) once daily for 4 weeks
Study: 1553856
Drug: 3.125 mg
Normalized name: carbidopa 3.125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.125 mg intravenous (IV) prochlorperazine
Study: 3828192
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg oral prochlorperazine
Study: 3857405
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (Cp) injections, both intradermal (i.c.) and subcutaneous (s.c.)
Study: 3857405
Drug: Corynebacterium parvum
Normalized name: Corynebacterium parvum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corynebacterium parvum (Cp) injections
Study: 23909409
Drug: Alitretinoin (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alitretinoin (30 mg oral dose)
Study: 23909409
Drug: Healthy controls
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy controls (30 mg oral dose of alitretinoin)
Study: 18672768
Drug: Somiton tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somiton tablet (Control)
Study: 16204431
Drug: Caffeine 250
Normalized name: caffeine 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 250 mg at 9:00 AM, 1:00 PM, and 6:00 PM after 5 days of abstinence from caffeine
Study: 16204431
Drug: Caffeine 300
Normalized name: caffeine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 300 mg/day and 600 mg/day for 5 days prior to challenge
Study: 16204431
Drug: Caffeine 0
Normalized name: caffeine 0.65 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 0 mg (control)
Study: 12403222
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) therapy at 20 ppm weaned to 5 ppm over 24-48 hours
Study: 11760378
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no iNO therapy)
Study: 10464845
Drug: HFA‐134a BDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: HFA‐134a BDP, 1600 mg total dose
Study: 10464845
Drug: CFC‐11/12 BDP,
Approvals — FDA: no, EMA: no, PMDA: no
Description: CFC‐11/12 BDP, 2000 mg total dose
Study: 2284328
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg naftidrofuryl daily per os
Study: 6776569
Drug: Butoctamide hydrogen
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butoctamide hydrogen succinate (600 mg)
Study: 6419633
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg midazolam i.m.
Study: 6419633
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg midazolam i.m.
Study: 6419633
Drug: 0.2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg/kg diazepam i.m.
Study: 6419633
Drug: 50 mg/50
Normalized name: Janumet 50 mg/500 mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg/50 mg pethidine/promethazine i.m.
Study: 22040838
Drug: Exercise training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise training with metformin (EM)
Study: 22040838
Drug: 2,000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2,000 mg/day metformin (M)
Study: 10664640
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1.0 and 2.0 g/d of elemental calcium)
Study: 1616164
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline solution, 10 mL epidurally and 3 mL intramuscularly (IM)
Study: 1616164
Drug: 10 mL
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mL of epidural saline solution and 75 mg (3 mL) of diclofenac IM
Study: 1616164
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of morphine in 10 mL of epidural saline solution and 3 mL of saline solution IM
Study: 1616164
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of morphine in 10 mL of epidural saline solution and 75 mg of diclofenac IM
Study: 31141291
Drug: Dynamic navigation
Normalized name: water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dynamic navigation system for implant placement
Study: 27050177
Drug: 15ml natural
Normalized name: Camphor (natural)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15ml natural honey applied on oral mucosa
Study: 27050177
Drug: 15ml plain
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15ml plain water applied on oral mucosa (Control)
Study: 19023841
Drug: Once-daily immunoassay
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily immunoassay test strips for urinary cotinine
Study: 19023841
Drug: Daily multiple
Normalized name: Daily Multiple Vitamins
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily multiple CO measurements
Study: 15841628
Drug: Lidocaine/tetracaine patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine/tetracaine patch (30-minute application)
Study: 12001006
Drug: Metronidazole 1%
Normalized name: METRONIDAZOLE 1% GEL,TOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronidazole 1% cream with sunscreen SPF 15
Study: 8652857
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Interferon-alpha and Hydroxyurea
Study: 1793694
Drug: Post-operative autotransfusion
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative autotransfusion with pre-operative aspirin
Study: 1793694
Drug: Post-operative autotransfusion
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative autotransfusion without pre-operative aspirin
Study: 25708818
Drug: Prednisolone treatment
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone treatment (control group)
Study: 10383546
Drug: WAG 994
Normalized name: acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: WAG 994 1 mg
Study: 8558223
Drug: Interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alfa-2b (IFN alpha-2b) administered at 20 MU/m2/d intravenously for 1 month and 10 MU/m2 three times per week subcutaneously for 48 weeks
Study: 6348227
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of amikacin 7.5 mg/kg intramuscularly
Study: 6348227
Drug: Sulfisoxazole 150
Normalized name: sulfisoxazole 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulfisoxazole 150 mg/kg/day orally for 10 days
Study: 29146124
Drug: Canakinumab 50
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 50 mg
Study: 29146124
Drug: Canakinumab 300
Normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Canakinumab 300 mg
Study: 24114811
Drug: AG013 (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG013 (oral rinse containing recombinant Lactococcus lactis secreting hTFF1)
Study: 19349543
Drug: Irinotecan plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan plus cisplatin (IP) - irinotecan 60 mg/m² on days 1, 8, and 15; cisplatin 60 mg/m² day 1, every 4 weeks
Study: 19349543
Drug: Etoposide plus
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Etoposide plus cisplatin (EP) - etoposide 100 mg/m² on days 1 through 3; cisplatin 80 mg/m² day 1, every 3 weeks
Study: 15479311
Drug: Target-controlled propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Target-controlled propofol infusion
Study: 15479311
Drug: Manual propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual propofol infusion
Study: 11528490
Drug: Oral dose
Normalized name: Exactamed Oral Dose Syringe 35cc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dose of iodized oil, containing 540 mg I
Study: 11367648
Drug: Xinmaitong (XMT)
Normalized name: XMT-2056
DrugBank: XMT-2056 (DB18230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinmaitong (XMT) capsule
Study: 11367648
Drug: Conventional western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional western medical therapy
Study: 7583724
Drug: Helical CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Helical CT with monophasic injections of contrast agent at 3 mL/second
Study: 7583724
Drug: Conventional CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CT with biphasic injections at 2 and 0.7 mL/second
Study: 1976782
Drug: (+/‐)‐propranolol base
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+/‐)‐propranolol base (0.108 mg kg‐1 of ideal body weight)
Study: 1976782
Drug: (+/‐)‐sotalol base
Approvals — FDA: no, EMA: no, PMDA: no
Description: (+/‐)‐sotalol base (1.06 mg kg‐1 of ideal body weight)
Study: 21623389
Drug: Combined infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined infusion of propofol and remifentanil
Study: 12724021
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with ten different estrogen or estrogen‐progestin molecules, regimens and routes of administration
Study: 12724021
Drug: HRT with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT with progestin molecules (except for 19‐nor derivatives) added to transdermal estradiol administration
Study: 7860905
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of amlodipine and atenolol
Study: 1424937
Drug: Generalized decision
Normalized name: celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generalized decision tree or clinical algorithm for treatment
Study: 3909587
Drug: Conventional immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppressive therapy (azathioprine and steroids)
Study: 3909587
Drug: Cyclosporin A
Normalized name: Cyclosporin A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A combined with steroids
Study: 30393955
Drug: Intensive statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive statin therapy targeting LDL cholesterol <1.81 mmol/L
Study: 30393955
Drug: Standard statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard statin therapy targeting LDL cholesterol ≥2.59 to <3.10 mmol/L
Study: 21538074
Drug: Long-term oral
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term oral appliance use
Study: 20129008
Drug: 2-day educational
Normalized name: DIABETES PATIENT EDUCATION PACK
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-day educational seminar and monthly group guidance for 6 months
Study: 12059059
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of FS and faecal occult blood test (FOBT)
Study: 9864836
Drug: TNFR55-IgG1 (2.5-100
Approvals — FDA: no, EMA: no, PMDA: no
Description: TNFR55-IgG1 (2.5-100 mg/month, given i.v., cumulative doses from 40-940 mg)
Study: 8589768
Drug: casein-soy VLED
Normalized name: caseins
Approvals — FDA: no, EMA: no, PMDA: no
Description: casein-soy VLED (96 g protein, 1.7 MJ/d)
Study: 2184790
Drug: Physician recognition
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Physician recognition of depression (defined by chart notation or prescription of antidepressants)
Study: 6965176
Drug: Cognitive family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive family therapy
Study: 29166854
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate 10 mL containing dezocine 0.1 mg/kg (Group D)
Study: 29166854
Drug: Ringer's lactate
Normalized name: Ringer's lactate/gel dressing 2.2" TOPICAL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate 10 mL (Group C)
Study: 26076191
Drug: Octreotide s.c.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide s.c. depot A 10, 20 or 30 mg, B 30 mg, C 10, 20 or 30 mg
Study: 26731483
Drug: Octreotide LAR
Normalized name: octreotide LAR 20 MG Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Octreotide LAR 30 mg
Study: 19266107
Drug: Flavored supplement
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flavored supplement (Group 1)
Study: 19266107
Drug: Non-flavored (neutral)
Normalized name: blackberry flavor
DrugBank: Blackberry (DB10628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-flavored (neutral) supplement (Group 2)
Study: 19266107
Drug: Kitchen foods
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kitchen foods as supplements (Group 3)
Study: 17056206
Drug: Medication coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication coaching plus voucher reinforcement for opening electronic medication caps on time
Study: 17056206
Drug: Medication coaching
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication coaching sessions every other week (comparison group)
Study: 15377466
Drug: G‐CSF 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 5 micro g/kg/day (group A)
Study: 15377466
Drug: G‐CSF 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: G‐CSF 10 micro g/kg/day (group B)
Study: 9863077
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of artesunate tablet over 3 days
Study: 9863077
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of artesunate tablet over 5 days
Study: 9863077
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of artesunate tablet over 7 days
Study: 7910560
Drug: Somatostatin-28 (S-28)
Normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin-28 (S-28) infusion
Study: 7910560
Drug: Somatostatin-14 (S-14)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin-14 (S-14) infusion
Study: 3302248
Drug: d,alpha-tocopherol (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: d,alpha-tocopherol (400 IU daily for three cycles)
Study: 18443980
Drug: Antipsychotic medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic medication (typical or atypical)
Study: 7048880
Drug: Pindolol 60
Normalized name: Pindolol
DrugBank: Pindolol (DB00960)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pindolol 60 mg
Study: 7048880
Drug: Pindolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (mean dose 50 mg/day)
Study: 7048880
Drug: Propranolol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (mean 360 mg/day)
Study: 7048880
Drug: Chlorthalidone (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorthalidone (mean 107 mg/day)
Study: 23711593
Drug: Miglitol and
Normalized name: Miglitol
DrugBank: Miglitol (DB00491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Miglitol and Mitiglinide combination
Study: 9784769
Drug: Prophylactic epoetin
Normalized name: Epoetin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic epoetin alfa therapy
Study: 3073077
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg three times/day)
Study: 3073077
Drug: Atenolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol (100 mg) plus Nifedipine (10 mg three times/day)
Study: 24827384
Drug: No treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No treatment (Control Group B)
Study: 16781360
Drug: eptifibatide +
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eptifibatide + reduced dose unfractionated heparin (n = 298)
Study: 16781360
Drug: eptifibatide +
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eptifibatide + reduced-dose enoxaparin (n = 275)
Study: 16781360
Drug: bivalirudin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: bivalirudin monotherapy (n = 284)